Collectively, these results indicated that methylstat treatment of glioma cells reduces the expression level of JMJD2A and inhibited its enzymatic activity, thereby providing a potential mechanism for its anti-glioma effects. The gene discussed is KDM4A; the disease is central nervous system cancer.